MAPT and Alzheimer disease: Recent immunoassay studies have identified increased levels of plasma p-tau181 and CSF chitinase-3-like protein 1 in patients following treatment in both phase II studies, along with increased levels of plasma GFAP in the LAURIET study, suggesting that semorinemab may stimulate glial activation in the presence of AD-associated tau pathology [159].